UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 1997

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________

Commission file number 0-20165

STERIS CORPORATION
(Exact name of registrant as specified in its charter)

OHIO	34-1482024
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)
5960 HEISLEY ROAD, MENTOR, OHIO	44060
(Address of principal executive offices)	(Zip Code)

(440) 354-2600
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No .

Indicate the number of shares outstanding of each of the issuer's classes of common shares, as of the latest practicable date.

Common Shares, without par value	33,907,037
(Title of Class)	(Outstanding at December 31, 1997)

PART I FINANCIAL INFORMATION

STERIS CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(IN THOUSANDS)
(UNAUDITED)

	DECEMBER 31, 1997	MARCH 31, 1997
ASSETS		
Current assets:		
Cash and cash equivalents	$ 16,601	$ 20,576
Marketable securities	883	2,977
Accounts receivable	195,175	164,163
Inventories	92,362	78,762
Current portion of deferred income taxes	24,577	24,888
Prepaid expenses and other assets	9,046	8,676
TOTAL CURRENT ASSETS	338,644	300,042
Property, plant, and equipment	283,707	177,184
Accumulated depreciation	(79,264)	(74,332)
Net property, plant, and equipment	204,443	102,852
Intangibles	248,693	186,417
Accumulated amortization	(68,874)	(67,032)
Net intangibles	179,819	119,385
Deferred income taxes	5,772	14,862
Other assets	4,819	2,314
TOTAL ASSETS	$ 733,497	$ 539,455
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Current portion of long-term indebtedness	$ 2,100	$ 12
Accounts payable	43,906	39,323
Accrued income taxes	31,978	19,059
Accrued expenses and other	117,040	100,294
TOTAL CURRENT LIABILITIES	195,024	158,688
Long-term indebtedness	153,204	35,879
Other liabilities	49,760	50,172
TOTAL LIABILITIES	397,988	244,739
Shareholders' equity:		
Serial preferred shares, without par value, 3,000 shares authorized; no shares outstanding		
Common Shares, without par value, 100,000 shares authorized; issued and outstanding shares of 33,907 at December 31, 1997 and 33,984 at March 31, 1997, excluding 332 and 255 treasury shares, respectively	227,015	231,278
Retained earnings	114,739	69,513
Cumulative translation adjustment	(6,245)	(6,075)
TOTAL SHAREHOLDERS' EQUITY	335,509	294,716
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 733,497	$ 539,455

See notes to consolidated condensed financial statements.

STERIS CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)

	THREE MONTHS ENDED DECEMBER 31		NINE MONTHS ENDED DECEMBER 31	
	1997	1996	1997	1996
Net revenues	$ 186,639	$ 151,005	$ 515,156	$ 417,363
Cost of goods and services sold	102,591	91,231	286,087	256,978
Gross profit	84,048	59,774	229,069	160,385
Costs and expenses:				
Selling, informational, and administrative	46,099	32,505	133,815	86,193
Research and development	5,989	5,425	17,919	15,598
Non-recurring items	0	0	0	90,831
	52,088	37,930	151,734	192,622
Income (loss) from operations	31,960	21,844	77,335	(32,237)
Interest expense	(2,453)	(192)	(3,848)	(2,140)
Interest income and other	263	715	638	3,512
Income (loss) before income taxes	29,770	22,367	74,125	(30,865)
Income tax expense	11,600	8,832	28,899	15,657
Net income (loss)	$ 18,170	$ 13,535	$ 45,226	$ (46,522)
Net income (loss) per share - basic	$ 0.54	$ 0.40	$ 1.33	$ (1.39)
Net income (loss) per share - diluted	$ 0.52	$ 0.38	$ 1.29	$ (1.39)

See notes to consolidated condensed financial statements.

STERIS CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(IN THOUSANDS) (UNAUDITED)

	NINE MONTHS ENDED DECEMBER 31	
	1997	1996
OPERATING ACTIVITIES		
Net income (loss)	$ 45,226	$ (46,522)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation and amortization	16,531	10,872
Deferred income taxes	1,066	51
Non-recurring items	0	53,261
Other items	(5,118)	5,581
Changes in operating assets and liabilities:		
Accounts receivable	(23,128)	(17,182)
Inventories	(12,675)	(3,078)
Other assets	(1,917)	1,697
Accounts payable and accruals	(20,371)	157
Accrued income taxes	5,835	2,242
NET CASH PROVIDED BY OPERATING ACTIVITIES	5,449	7,079
INVESTING ACTIVITIES		
Purchases of property, plant, equipment, and patents	(29,377)	(12,231)
Investment in businesses	(126,505)	(82,482)
Sale of assets	43,084	0
Proceeds from notes receivable	0	8,438
Purchases of marketable securities	0	(4,068)
Proceeds from sales of marketable securities	2,094	7,147
NET CASH USED IN INVESTING ACTIVITIES	(110,704)	(83,196)
FINANCING ACTIVITIES		
Payments on long-term obligations	(4,287)	(100,035)
Borrowing under Credit Facility	110,000	40,000
Purchase of treasury shares	(10,051)	0
Proceeds from exercise of stock options	4,645	26,086
Tax benefits from exercise of stock options	1,143	3,419
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	101,450	(30,530)
Effect of exchange rate changes on cash and cash equivalents	(170)	681
DECREASE IN CASH AND CASH EQUIVALENTS	(3,975)	(105,966)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	20,576	140,788
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$ 16,601	$ 34,822

See notes to consolidated condensed financial statements.

STERIS CORPORATION
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)

Periods Ended December 31, 1997 and 1996

A. - REPORTING ENTITY

STERIS Corporation (the "Company" or "STERIS") is a leading provider of infection prevention, contamination prevention, microbial reduction, and surgical support systems, products, services, and technologies to healthcare, scientific, research, and industrial Customers throughout the world. The Company has over 4,000 Associates (employees) worldwide, including more than 1,200 direct sales, service, and field support personnel. Customer Support facilities are located in major global market centers with manufacturing operations in the United States, Canada, Germany, and Finland. STERIS operates in a single business segment.

B. - BASIS OF PRESENTATION

On May 13, 1996, STERIS merged with Amsco International, Inc. ("Amsco") in a tax-free, stock-for-stock transaction (the "Amsco Merger"). The Amsco Merger has been accounted for using the pooling-of-interests method. Accordingly, the accompanying unaudited consolidated condensed financial statements give retroactive effect to the Amsco Merger and include the combined operations of STERIS and Amsco for all periods presented.

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q; they do not include all of the information and footnotes required by generally accepted accounting principles for complete audited financial statements. Accordingly, the reader of these financial statements may wish to refer to the audited consolidated financial statements of STERIS filed with the Securities and Exchange Commission as part of STERIS's Form 10-K for the year ended March 31, 1997.

The accompanying consolidated condensed financial statements have been prepared in accordance with STERIS's customary accounting practices and have not been audited. Management believes that the financial information included herein reflects all adjustments necessary for a fair presentation of interim results and, except as discussed in Note D, all such adjustments are of a normal and recurring nature. The interim results reported are not necessarily indicative of the results to be expected for the fiscal year ending March 31, 1998.

STERIS CORPORATION
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)

C. - EARNINGS (LOSS) PER SHARE

In 1997, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 128, "Earnings per Share." Statement 128 eliminates reporting of primary and fully diluted earnings per share and requires reporting of basic and diluted earnings per share. Basic earnings per share is based on average Common Shares outstanding. Diluted earnings per share includes the dilutive effect of stock options. All earnings per share amounts presented conform to the Statement 128 requirements. Following is a summary, in thousands, of Common Shares and Common Share equivalents outstanding used in the calculations of earnings (loss) per share:

	THREE MONTHS ENDED DECEMBER 31		NINE MONTHS ENDED DECEMBER 31	
	1997	1996	1997	1996
Weighted average Common Shares outstanding - basic	33,904	34,161	33,943	33,535
Dilutive effect of stock options	1,214	1,928	1,127	0
Weighted average Common Shares and equivalents - diluted	35,118	36,089	35,070	33,535

D. - NON-RECURRING ITEMS

During the second quarter of fiscal 1998, STERIS completed the sale of the assets of its Management Services Division to General Electric Medical Systems, a business of General Electric Company. The transaction did not result in a material income statement effect. Costs related to the transaction include tangible and intangible assets relating to the business, impairment cost of redundant assets, and transaction related costs. These costs are based on estimates and may be adjusted in the future.

Non-recurring charges of $90,831 ($81,300 net of tax, or $2.44 per share) were recorded in the 1997 fiscal first quarter for costs related to the Amsco Merger. The charges include transaction costs of approximately $15,000 and other non-recurring charges of approximately $75,800 ($66,300 net of tax). The transaction costs were for legal, accounting, investment banking, and related expenses. The other non-recurring charges were for (i) elimination of redundant facilities and other assets ($27,000), (ii) satisfaction of Amsco executive employment agreements and other Associate severance ($19,300), (iii) write-off of goodwill related to Amsco's Finn-Aqua business ($27,250), and (iv) other merger-related items. Property write downs of $20,000 were recorded as part of the estimated cost of eliminating redundant facilities based on fair value estimates. During fiscal 1997, STERIS closed a manufacturing and research facility in Apex, North Carolina, Amsco's headquarters in Pittsburgh, Pennsylvania, as well as Customer Service

STERIS CORPORATION
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)

facilities in Dallas, Texas and Atlanta, Georgia. Operations of the closed facilities were consolidated into existing STERIS facilities.

The effective income tax rate for the nine months ended December 31, 1996 differed from statutory rates principally because certain non-recurring items that increased the net loss are non-deductible for tax purposes. Non-deductible items include the write-off of goodwill related to Amsco's Finn-Aqua business and provisions for certain executive severance costs. Also, additional tax valuation allowances were provided to reflect the effects of merger activities.

E. - INVENTORIES

Inventories were as follows:

	DECEMBER 31, 1997	MARCH 31, 1997
Raw material	$31,581	$30,027
Work in process	18,504	15,240
Finished goods	42,277	33,495
	$92,362	$78,762

F. - FINANCING

During the first fiscal quarter 1998, STERIS increased the amount available for borrowing under its unsecured revolving Credit Facility from $125,000 to $215,000. The amended Credit Facility expires September 30, 2001 and may be used for general corporate purposes. Loans under the Credit Facility will bear interest, at STERIS's option, at either KeyBank National Association's prime rate or LIBOR rates plus 0.25 percent to 0.35 percent. The Credit Facility contains customary covenants which include maintenance of certain financial ratios. Outstanding borrowings under the Credit Facility were $145,000 at December 31, 1997.

Additional obligations consist mainly of industrial development revenue bonds which bear interest at a variable rate based on the bank/marketing agent's demand note index. These bond agreements contain various covenants relating to minimum capitalization, net worth, and working capital. Outstanding obligations under the industrial development revenue bonds were $8,000 at December 31, 1997.

G. - CONTINGENCIES

There are various pending lawsuits and claims arising out of the conduct of STERIS's business. In the opinion of management, the ultimate outcome of these lawsuits and claims will not have a material adverse effect on STERIS's consolidated financial position or results of operations. STERIS presently maintains product liability insurance coverage in amounts and with

STERIS CORPORATION
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) (UNAUDITED)

deductibles that it believes are prudent.

H. - ACQUISITIONS

On September 17, 1997, the Company acquired all of the shares of common stock of Isomedix Inc. in exchange for cash of $134,102. Isomedix is a leading provider of contract sterilization and microbial reduction services, with gamma irradiation, ethylene oxide, and electron-beam processing facilities across North America. The acquisition has been accounted for as a purchase transaction. The following is a preliminary allocation of the purchase price:

Current assets	$ 21,778
Property, plant, and equipment	94,546
Excess purchase price over net assets acquired	63,000
Other assets	1,044
Current liabilities	(30,096)
Long-term debt	(7,900)
Deferred income taxes	(8,270)
Total cost of acquisition	$ 134,102

The following unaudited pro forma results of operations assume the acquisition occurred on April 1, 1996. These pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations which actually would have resulted had the acquisition occurred on the date indicated, or which may result in the future.

	Nine Months Ended December 31	
	1997	1996
Net revenues	$ 536,426	$ 450,751
Income (loss) from continuing operations	$ 45,123	$ (45,686)
Income (loss) from discontinued operations	200	(258)
Net income (loss)	$ 45,323	$ (45,944)
Income (loss) from continuing operations per share - diluted	$ 1.28	$ (1.36)
Net income (loss) per share - diluted	$ 1.29	$ (1.37)

In July 1997, STERIS acquired Joslyn Sterilizer Corporation, a designer and manufacturer of high quality, high performance sterile processing systems based upon widely accepted steam and gas sterilization methodologies. The acquisition was accounted for as a purchase transaction and did not have a material effect on the operations of the Company.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

BASIS OF DISCUSSION

The Amsco Merger has been accounted for by the pooling-of-interests method. Accordingly, the accompanying unaudited consolidated condensed financial statements give retroactive effect to the transaction and include the combined operations of STERIS and Amsco for all periods presented.

RESULTS OF OPERATIONS

Net revenue increased by 23.6% to $186.6 million in the third quarter fiscal 1998 from $151.0 million in the third quarter fiscal 1997. Net revenue increased by 23.4% to $515.2 million in the first nine months of fiscal 1998 from $417.4 million in the same period in fiscal 1997. Infection Prevention revenues increased by 22.8% to $98.7 million in the third quarter fiscal 1998 from $80.4 million in the third quarter fiscal 1997. Infection Prevention revenues increased by 25.2% to $279.0 million in the first nine months of fiscal 1998 from $222.9 million in the same period in fiscal 1997. Surgical Support revenues increased by 37.1% to $41.3 million in the third quarter fiscal 1998 from $30.1 million in the third quarter fiscal 1997. Surgical Support revenues increased by 24.4% to $113.0 million in the first nine months of fiscal 1998 from $90.8 million in the same period in fiscal 1997. Scientific, Management Services and Other revenue increased by 15.1% to $46.7 million in the third quarter fiscal 1998 from $40.5 million in the third quarter fiscal 1997. Scientific, Management Services and Other revenue increased by 18.8% to $123.2 million in the first nine months of fiscal 1998 from $103.7 million in the same period in fiscal 1997. The increase in net revenues was due mainly to increases in the sales of consumable products and capital equipment during the first nine months of fiscal 1998, as well as an increase in Management Services revenues through the acquisition of Isomedix. Revenues related to the Infection Prevention, Surgical Support, and Scientific, Management Services and Other classifications each include revenues related to consumable products, capital equipment and services. In addition to increases in sales of existing products, a portion of the increase in sales of consumable products results from the benefits of the December 1996 acquisition of the assets of the infection control and contamination control businesses of Calgon Vestal Laboratories, and the fiscal second quarter 1997 acquisition of Surgicot, Inc., a manufacturer and supplier of biological and chemical sterile process monitors, sterilization wraps and pouches, and other quality assurance products.

The costs of products and services sold increased by 12.5% to $102.6 million in the third quarter fiscal 1998 from $91.2 million in the third quarter fiscal 1997. The costs of products and services sold increased by 11.3% to $286.1 million for the first nine months of fiscal 1998 from $257.0 million for the first nine months of fiscal 1997. The cost of products and services sold as a percentage of net revenue was 55.0% for the third quarter fiscal 1998 compared to 60.4% for the same period in fiscal 1997. The decrease in the cost of products and services sold as a percentage of net revenue for the third quarter fiscal 1998 resulted principally from favorable changes in the mix of products sold, vertical integration, improved overhead absorption from plant consolidation and volume increases, and the benefits from the restructuring of the acquired and merged businesses.

Selling, informational, and administrative expenses increased by 41.8% to $46.1 million in the third quarter fiscal 1998 from $32.5 million in the third quarter fiscal 1997. Selling, informational, and administrative expenses increased by 55.3% to $133.8 million in the first nine months of fiscal 1998 from $86.2 million in the first nine months of fiscal 1997. The expenses as a percentage of net revenue increased to 24.7% in the third quarter fiscal 1998 from 21.5% in the third quarter fiscal 1997. The increase was primarily attributable to the acquisition of Isomedix, investments in Customer Support, direct sales efforts in key global markets, business development, management information systems, and the inclusion of acquired companies' selling, informational, and administrative expenses.

Selling, informational, and administrative expenses include costs incurred in preparing certain systems and applications for the year 2000. The Company expects to incur internal staff costs as well as external costs related to the conversion and testing of certain systems and applications that currently do not recognize dates beginning in the year 2000. These costs, which are expensed as incurred, have been immaterial to date and are not expected to have a material impact on the Company's earnings in the future.

The costs of the Company's research activities relating to the discovery and development of new products and the improvement of existing products are charged directly to income as incurred. Research and development expenses increased by 10.4% to $6.0 million in the third quarter fiscal 1998 from $5.4 million in the third quarter fiscal 1997. Research and development expenses increased by 14.9% to $17.9 million in the first nine months of fiscal 1998 from $15.6 million in the first nine months of fiscal 1997. The increases were due to additional product and application development expenditures. Research and development expenses as a percentage of net revenue were 3.2% for the third quarter fiscal 1998 compared to 3.6% for the third quarter fiscal 1997.

Interest expense increased to $2.5 million in the third quarter fiscal 1998 from $0.2 million in the third quarter fiscal 1997. Interest expense increased by 79.8% to $3.8 million in the first nine months of fiscal 1998 from $2.1 million in the first nine months of fiscal 1997. The increase was due to the additional borrowing under the Credit Facility for the purchase of Isomedix common shares.

Interest income and other decreased by 63.2% to $0.3 million in the third quarter fiscal 1998 from $0.7 million in the third quarter fiscal 1997. Interest income and other decreased by 81.8% to $0.6 million in the first nine months of fiscal 1998 from $3.5 million in the first nine months of fiscal 1997. The decrease in interest income was due primarily to lower cash, cash equivalents, and marketable security balances, with the lower balances resulting primarily from the July 1996 redemption of approximately $100 million of Amsco 4.5%/6.5% Convertible Subordinated Notes.

Income for the third quarter of fiscal 1998 increased by 34.2% to $18.2 million ($.52 per share) from $13.5 million ($.38 per share) in the same period fiscal 1997. Excluding the effect of non-recurring items, income for the first nine months of fiscal 1998 increased by 30.0% to $45.2 million ($1.29 per share) from $34.8 million ($.98 per share) in the first nine months of fiscal 1997.

The effective income tax rate for the nine months ended December 31, 1996 differed from statutory rates principally because certain non-recurring items that increased the net loss are non-deductible for tax purposes. Non-deductible items include the write-off of goodwill related to Amsco's Finn-Aqua business and provisions for certain executive severance costs. Also, additional tax valuation allowances were provided to reflect the effects of merger activities.

As a result of the foregoing factors, net income for the first nine months of fiscal 1998 was $45.2 million, compared to a net loss of $46.5 million in the first nine months of fiscal 1997.

LIQUIDITY AND CAPITAL RESOURCES

The Company had $17.5 million in cash, cash equivalents and marketable securities as of December 31, 1997, compared to $23.6 million of the same at March 31, 1997. The decrease was due mainly to cash paid for the acquisitions of Isomedix and Joslyn and the purchases of property, plant, and equipment offset by cash received through borrowings under the Credit Facility and the sale of assets.

Accounts receivable increased by 18.9% to $195.2 million as of December 31, 1997, compared to $164.2 million at March 31, 1997. The increase was due mainly to the increase in revenues and the acquisition of businesses.

Inventory increased by 17.3% to $92.4 million as of December 31, 1997, compared to $78.8 million at March 31, 1997. The increase was due to the build up of inventory to support increased sales volume.

Property, plant, and equipment increased by 60.1% to $283.7 million as of December 31, 1997, compared to $177.2 million at March 31, 1997. The increase was primarily a result of the acquisitions of Isomedix and Joslyn.

Intangibles increased by 33.4% to $248.7 million as of December 31, 1997, compared to $186.4 million at March 31, 1997. The increase was primarily a result of the acquisitions of Isomedix and Joslyn.

Deferred tax assets decreased by 61.2% to $5.8 million as of December 31, 1997, compared to $14.9 million at March 31, 1997. The decrease was primarily a result of the acquisition of Isomedix.

Current liabilities increased by 22.9% to $195.0 million as of December 31, 1997, compared to $158.7 million at March 31, 1997. The increase was due to the assumption of liabilities through the acquisitions of Isomedix and Joslyn and the accrual of costs relating to the sale of the assets of the Management Services Division.

Other liabilities were $49.8 million as of December 31, 1997, compared to $50.2 million of the same at March 31, 1997.

During the first fiscal quarter 1998, STERIS increased the amount available for borrowing under its unsecured revolving Credit Facility from $125 million to $215 million. The amended Credit Facility expires September 30, 2001 and may be used for general corporate purposes. Loans under the Credit Facility will bear interest, at STERIS's option, at either KeyBank National Association's prime rate or LIBOR rates plus 0.25 percent to 0.35 percent. The Credit Facility contains customary covenants which include maintenance of certain financial ratios. Outstanding borrowings under the Credit Facility were $145 million at December 31, 1997.

Additional obligations consist mainly of industrial development revenue bonds which bear interest at a variable rate based on the bank/marketing agent's demand note index. These bond agreements contain various covenants relating to minimum capitalization, consolidated net worth, and working capital. Outstanding obligations under the industrial development revenue bonds were $8,000 at December 31, 1997.

The Company has no material commitments for capital expenditures. The Company believes that its cash requirements will increase due to increased sales requiring more working capital, accelerated research and development, and potential acquisitions or investments in complementary businesses. However, the Company believes that its available cash, cash flow from operations, and sources of credit will be adequate to satisfy its capital needs for the foreseeable future.

CONTINGENCIES

For a discussion of contingencies, see Note G to the consolidated condensed financial statements.

SEASONALITY

Historical data indicates that financial results of acquired businesses, including Amsco, were subject to recurring seasonal fluctuations. A number of factors have contributed to the seasonal patterns, including sales promotion and compensation programs, customer buying patterns, international business practices, and differing fiscal year ends. Sales and profitability of certain of the acquired and consolidated product lines have historically been disproportionately weighted toward the latter part of each quarter and each fiscal year. Various changes in business practices resulting from the integration of Amsco and other acquired businesses into STERIS, including the change to a March ending fiscal year, may alter the historical patterns of the previously independent businesses.

FORWARD-LOOKING INFORMATION

This Form 10-Q contains statements concerning certain trends and other forward-looking information affecting or relating to the Company and its industry that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. There are many important factors that could cause actual results to differ materially from those in the forward-looking statements. Many of these important factors are outside STERIS's control. Changes in market conditions, including competitive factors and changes in government regulations, could cause actual results to differ materially from the Company's expectations. No assurance can be provided as to any future financial results. Other potentially negative factors that could cause actual results to differ materially from those in the forward-looking statements include (a) the possibility that the continuing integration of acquired businesses will take longer than anticipated, (b) the potential for increased pressure on pricing that leads to erosion of profit margins, (c) the possibility that market demand will not develop for new technologies, products, and applications, (d) the potential effects of fluctuations in foreign currencies, and (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products.

PART II OTHER INFORMATION

ITEM 1 LEGAL PROCEEDINGS

Reference is made to Part I, Item 1., Note G of this Report on Form 10-Q, which is incorporated herein by reference.

ITEM 6 EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

EXHIBIT NUMBER	EXHIBIT DESCRIPTION
27.1	Financial Data Schedule

(b) Reports on Form 8-K

None

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

STERIS Corporation
(Registrant)

/s/ Michael A. Keresman, III

Michael A. Keresman, III
Chief Financial Officer and
Senior Vice President
(Principal Financial Officer)
February 13, 1998

9-MOS
MAR-31-1998
DEC-31-1997
16,601
883
195,175
0
92,362
338,644
283,707
(79,264)
733,497
195,024
0
0
0
227,015
108,494
733,497
515,156
515,156
286,087
286,087
0
0
3,848
74,125
28,899
45,226
0
0
0
45,226
1.33
1.29